Market open
Clene/$CLNN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Clene
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
Ticker
$CLNN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
84
Website
Clene Metrics
BasicAdvanced
$36M
-
-$5.58
0.32
-
Price and volume
Market cap
$36M
Beta
0.32
52-week high
$10.40
52-week low
$3.82
Average daily volume
50K
Financial strength
Current ratio
0.827
Quick ratio
0.615
Long term debt to equity
-273.309
Total debt to equity
-554.691
Interest coverage (TTM)
-7.24%
Management effectiveness
Return on assets (TTM)
-46.69%
Return on equity (TTM)
-416.92%
Valuation
Price to revenue (TTM)
65.514
Price to book
-7.1
Price to tangible book (TTM)
-7.1
Price to free cash flow (TTM)
-1.164
Growth
Revenue change (TTM)
-41.37%
Earnings per share change (TTM)
-37.48%
3-year revenue growth (CAGR)
-8.69%
3-year earnings per share growth (CAGR)
1.68%
What the Analysts think about Clene
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Clene stock.
Clene Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Clene Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Clene News
AllArticlesVideos
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
GlobeNewsWire·1 day ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Clene stock?
Clene (CLNN) has a market cap of $36M as of February 26, 2025.
What is the P/E ratio for Clene stock?
The price to earnings (P/E) ratio for Clene (CLNN) stock is 0 as of February 26, 2025.
Does Clene stock pay dividends?
No, Clene (CLNN) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Clene dividend payment date?
Clene (CLNN) stock does not pay dividends to its shareholders.
What is the beta indicator for Clene?
Clene (CLNN) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.